Imagion Biosystems has lodged the announcement “Pro-Rata Non-Renounceable Rights Issue” with the Australian Securities Exchange.
View the announcement “Pro-Rata Non-Renounceable Rights Issue.”
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce